Many may not realize that not all stomach cancers are created equal and that they can vary significantly. This variation may lead to requiring differing treatments based on the type and severity of the cancer.
4 specific genes have been discovered that clue in on how stomach cancers can progress and develop, according to a recent study presented at the Digestive Disease Week conference. Researchers found that mutations in BRCA2, CDH1, RHOA, and TP53 were strongly linked to more aggressive forms of gastric cancer and poorer patient outcomes.
In the study, scientists analyzed tumor samples from 87 patients who had undergone surgery and chemotherapy. About one-third of these patients carried mutations in this four-gene combination, and those individuals were found to significantly be more likely to experience cancer recurrence or reduced survival. These findings highlight that certain genetic signatures can act as early warning signs for how deadly a tumor may become.
This discovery offers hope for more personalized treatment plans, rather than what is typically done currently where all stomach cancers are treated relativley the same despite their differences. This discovery can prevent using aggressive treatments on those that do not need it, and also provide better plans for those who do need it.
While promising, these results are still considered preliminary and much further research is still needed before being able to widley use this information in a clinical setting.
News Article Source: https://www.usnews.com/news/health-news/articles/2025-04-25/four-gene-combo-might-predict-lethality-of-stomach-cancer
More on Stomach Cancer: https://www.cancer.org/cancer/types/stomach-cancer/about.html
No comments:
Post a Comment